New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
12:06 EDTBBEP, SFLY, CHRW, BPI, NVSHigh option volume stocks: BBEP SFLY CHRW BPI NVS
News For BBEP;SFLY;CHRW;BPI;NVS From The Last 14 Days
Check below for free stories on BBEP;SFLY;CHRW;BPI;NVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2014
13:23 EDTSFLYShutterfly climbs higher after Hellman, others submit acquisition offers
Subscribe for More Information
12:37 EDTSFLYOn The Fly: Midday Wrap
Subscribe for More Information
12:06 EDTNVSNovartis treatment for pigmented villonodular synovitis gets orphan designation
According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link
11:47 EDTSFLYShutterfly more likely to be acquired by private equity firm, says RW Baird
Subscribe for More Information
10:40 EDTSFLYShutterfly calls active on PE firms bidding report
Shutterfly September 55 and 60 calls are active on total call volume of 3K contracts (1K puts) on Hellman & Friedman is one of the private equity firms that submitted takeover bids to acquire, Bloomberg reports. September call option implied volatility is at 38, December is at 32, January is at 27; compared to its 26-week average of 37 according to Track Data. Active call volume suggests traders taking positions for large price movement.
10:29 EDTSFLYHellman among PE firms bidding for Shutterfly, Bloomberg reports
Hellman & Friedman is one of the private equity firms that submitted takeover bids to acquire Shutterfly, Bloomberg reports, citing people with knowledge of the matter. Shutterfly could be valued at about $2B in a sale, but the company has received little interest from technology and Internet names, Bloomberg adds. Shares of online photo service rallied 3%, or $1.31, to $51.15 following the report. Reference Link
10:21 EDTSFLYShutterfly valued at about $2B by bidders, Bloomberg reports
10:20 EDTSFLYHellman & Friedman submitted bid to acquire Shutterfly, Bloomberg says
Subscribe for More Information
05:17 EDTNVSNovartis provides drug candidate compounds to TB Alliance
Subscribe for More Information
August 19, 2014
12:34 EDTBBEPBreitBurn Energy, QR Energy receive early termination of HSR waiting period
Subscribe for More Information
05:11 EDTNVSGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
August 18, 2014
07:35 EDTNVSApricus Biosciences launches topical ED treatment in Germany
Subscribe for More Information
August 14, 2014
14:55 EDTSFLYShutterfly calls active on being eyed by several PE firms, report says
Subscribe for More Information
14:40 EDTSFLYShutterfly being eyed by several PE firms, TheStreet says
Subscribe for More Information
13:37 EDTSFLYShutterfly rises, move attributed to positive comments from TheDeal
Subscribe for More Information
August 11, 2014
05:18 EDTNVSNovartis reports LCZ696 significantly reduced cardiovascular deaths
New data revealing the reduction in cardiovascular, or CV, deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction, or HF-REF, will be presented at the European Society of Cardiology, or ESC, Congress 2014. The 8,442 patient study, PARADIGM-HF, was specifically designed to see if LCZ696 could increase survival over and above what can be achieved with ACE-inhibitor enalapril in addition to current best treatment in HF-REF patients. In March the Data Monitoring Committee overseeing the study confirmed those given LCZ696 were significantly less likely to die from CV causes, leading to the trial being closed early. LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF. PARADIGM-HF is the largest heart failure study ever conducted and was stopped early in March due to compelling efficacy. LCZ696 was recently granted FDA Fast Track status and rolling submission expected to be complete by end of year.
August 8, 2014
06:51 EDTNVSJudge rules DOJ can pursue Novartis kickback suit, Reuters says
U.S. District Judge Colleen McMahon ruled that the U.S. Department of Justice is allowed to continue its False Claims Act lawsuit versus Novartis regarding allegations that the company used kickbacks to increase sales of medications covered by Medicare and Medicaid, according to Reuters, citing comments from McMahon. Reference Link
August 7, 2014
08:38 EDTNVSEnanta's HCV NS5A inhibitor EDP-239 advances into combination studies
Subscribe for More Information
07:13 EDTBPIBridgepoint Education reports Q2-end total student enrollment was 61,117
Subscribe for More Information
07:13 EDTBPIBridgepoint Education reports Q2 EPS 28c, may not be comparable to consensus 14c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use